autologous blood and marrow transplantation - Blog Science ...

More documents

Recommendations

Info

0-9 LIST OF ABBREVIATIONS 2CDA 2-chlordeoxyadenosine 4HC hydroperoxycyclophosphamide A ABMTR-NA .. .Autologous Blood and Marrow Transplant Registry of North America ABVD doxorubicin, bleomycin, vinblastine, daccarbazine AILD angioimmunoblastic lymphadenopathy-like T cell lymphoma ALL acute lymphoblastic leukemia alloBMT allogeneic bone marrow transplantation AML acute myeloid leukemia ANC absolute neutrophil count AP accelerated phase APC antigen-presenting cell Ara-C cytosine arabinoside ASO allele-specific oligonucleotide ATG antithymocyte globulin autoBMT autologous bone marrow transplantation B BAVC BCNU, M-AMSA, VP16, cytosine arabinoside BC blast crisis BCNU carmustine (nitrosourea) BEAC BCNU, etoposide, cytosine arabinoside, cyclophosphamide BEAM BCNU, etoposide, cytosine arabinoside, melphalan BEP bleomycin, etoposide, cisplatin BFU-E burst forming unit-erythroid BMMNC bone marrow mononuclear cells BMT bone marrow transplantation C CAE cyclophosphamide, doxorubicin, etoposide
Page 1: AUTOLOGOUS BLOOD AND MARROW TRANSPL
Page 5 and 6: AUTOLOGOUS BLOOD AND MARROW TRANSPL
Page 7: ACKNOWLEDGMENTS We wish to thank Wi
Page 11: THE VAN BEKKUM STEM CELL AWARD Prof
Page 14 and 15: xii Table of Contents CHAPTER 2: AL
Page 16 and 17: xiv Table of Contents Late Non-Rela
Page 18 and 19: xvi Table of Contents Pretreatment
Page 20 and 21: xviii Table of Contents CHAPTER 7:
Page 22 and 23: XX Table of Contents Long-Term Obse
Page 24 and 25: xxii Table of Contents CHAPTER 13:
Page 28 and 29: xxvi List of Abbreviations CAV cisp
Page 30 and 31: xxviii List of Abbreviations I IBC
Page 32 and 33: xxx List of Abbreviations PSS progr
Page 35: CHAPTER 1 AML
Page 38 and 39: 4 Chapter 1: AML contribute to rela
Page 40 and 41: 6 Chapter 1: AML Table 1. Purging e
Page 42 and 43: 8 Chapter 1: AML graft. We plan to
Page 44 and 45: 10 Chapter 1: AML years that a sign
Page 46 and 47: 12 Chapter 1: AML Subgroup Risk gro
Page 48 and 49: 14 Chapter 1: AML 2. Zittoun RA, Ma
Page 50 and 51: 16 Chapter I: AML placebo-controlle
Page 52 and 53: 18 Chapter 1: AML 6. Hellstrand K,
Page 54 and 55: 20 Chapter 1: AML apheresis after G
Page 56 and 57: 22 Chapter 1: AML Table 1. Clinical
Page 58 and 59: 24 Chapter 1: AML exhibit low-densi
Page 60 and 61: 26 Chapter 1: AML Disease-Free Surv
Page 62 and 63: 28 Chapter 1: AML Disease-Free Surv
Page 64 and 65: 30 Chapter 1: AML 2 CO Disease-Free
Page 66 and 67: 32 Chapter 1:AML Table 3. Probabili
Page 68 and 69: 34 Chapter 1: AML Eric Martin (Medi
Page 70 and 71: 36 Chapter 1: AML 23. Howell AL, Ba
Page 72 and 73: Autologous Blood Cell Transplantati
Page 74 and 75: 40 Chapter 1: AML quarter of the pa
Page 76 and 77:
42 Chapter 1: AML of the EBMT. 32 A
Page 78 and 79:
44 Chapter 1: AML 7. O'Donnell MR,
Page 80 and 81:
Immunotherapy With IL-2 After Autol
Page 82 and 83:
48 Chapter 1: AML Several centers h
Page 84 and 85:
50 Chapter 1 : AML occur within the
Page 86 and 87:
52 Chapter 1: AML Information Scien
Page 89:
CHAPTER 2 ALL
Page 92 and 93:
58 Chapter 2: ALL Table 1. Comparis
Page 94 and 95:
60 Chapter 2: ALL UKALL XII). This
Page 96 and 97:
Adult ALL: BMT in First Remission f
Page 98 and 99:
64 Chapter 2: ALL leukemia) appears
Page 100 and 101:
66 Chapter 2: ALL recent update, ho
Page 102 and 103:
68 Chapter 2: ALL in parallel, and
Page 104 and 105:
70 Chapter 2: ALL A, Prentice G, Gl
Page 106 and 107:
Autologous Hematopoietic Stem Cell
Page 108 and 109:
74 Chapter 2: ALL Table 1. Patient
Page 110 and 111:
76 Chapter 2: ALL Table 3. Hematolo
Page 112 and 113:
78 Chapter 2: ALL 1,0 i j CR3 (n= 3
Page 114 and 115:
80 Chapter 2: ALL 20 40 60 < 5 week
Page 116 and 117:
82 Chapter 2: ALL Other aspects reg
Page 118 and 119:
Autologous BMT/PBSCT in BCR-ABL-pos
Page 120 and 121:
86 Chapter 2: ALL ABMT/PBSCT in CR2
Page 122 and 123:
88 Chapter 2: ALL Induction I Induc
Page 124 and 125:
90 Chapter 2: ALL CONCLUSIONS Molec
Page 126 and 127:
92 Chapter 2: ALL Adult Philadelphi
Page 128 and 129:
94 Chapter 2: ALL BMT. Transplantat
Page 130 and 131:
96 Chapter 2: ALL Table 1. Summary
Page 132 and 133:
98 Chapter 2: ALL 5:01 2.5:1 1.25:1
Page 134 and 135:
100 Chapter 2: ALL 11. Passweg JR,
Page 137 and 138:
Donor Lymphocyte Infusions Produce
Page 139 and 140:
Carella et al. later, and the other
Page 141 and 142:
Carella et al. Evaluation of chimer
Page 143 and 144:
Carella et al. erythropoietin follo
Page 145 and 146:
Autografring for Chronic Myeloid Le
Page 147 and 148:
Preclinical Evaluation of an Inhibi
Page 149 and 150:
Hehlmann et al. 115 idarubicin, Ara
Page 151 and 152:
BMT Hehimann et ai. 117 Diagnosis /
Page 153 and 154:
Hehlmann et al. 119 Table 4. Correl
Page 155 and 156:
Allocation: suitable for transplant
Page 157 and 158:
Hehlmann et al. 123 2. The Italian
Page 159 and 160:
Br J Haematol 23:283-288,1972. Hehl
Page 161 and 162:
Hehlmann et al. 127 JA, Dexter TM,
Page 163 and 164:
Carlo-Stella et al. 129 INTRODUCTIO
Page 165 and 166:
Carlo-Stella et al. 131 DNA fragmen
Page 167 and 168:
Carlo-Stella et al. 133 particularl
Page 169 and 170:
Carlo-Stella et al. 135 10. De Fabr
Page 171:
CHAPTER 4 LYMPHOMA
Page 174 and 175:
Late Non-Relapse Mortality After Au
Page 176 and 177:
142 Chapter 4: Lymphoma Table 2. Tr
Page 178 and 179:
144 Chapter 4: Lymphoma 1.0 1 0.4 J
Page 180 and 181:
146 Chapter 4: Lymphoma after autoS
Page 182 and 183:
148 Chapter 4: Lymphoma etoposide f
Page 184 and 185:
150 Chapter 4: Lymphoma age, sex, d
Page 186 and 187:
152 Chapter 4: Lymphoma Mobilizatio
Page 188 and 189:
154 Chapter 4: Lymphoma Missing dat
Page 190 and 191:
156 Chapter 4: Lymphoma Table 3. Ef
Page 192 and 193:
158 Chapter 4: Lymphoma REFERENCES
Page 194 and 195:
160 Chapter 4: Lymphoma Blood 79:10
Page 196 and 197:
162 Chapter 4: Lymphoma Gribben et
Page 198 and 199:
164 Chapter 4: Lymphoma purging. Si
Page 200 and 201:
Local and Regional Recurrence After
Page 202 and 203:
168 Chapter 4: Lymphoma and autoSCT
Page 204 and 205:
170 Chapter 4: Lymphoma Local or lo
Page 206 and 207:
172 Chapter 4: Lymphoma %OS 100 i 8
Page 208 and 209:
174 Chapter 4: Lymphoma %os 100. 80
Page 210 and 211:
176 Chapter 4: Lymphoma A 100 % RFS
Page 212 and 213:
178 Chapter 4: Lymphoma 100 80 %OS
Page 214 and 215:
180 Chapter 4: Lymphoma vs. sensiti
Page 216 and 217:
182 Chapter 4: Lymphoma therapy wit
Page 218 and 219:
High-Dose Therapy Followed by Hemat
Page 220 and 221:
186 Chapter 4: Lymphoma autoBMT in
Page 222 and 223:
188 Chapter 4: Lymphoma diameter. R
Page 224 and 225:
190 Chapter 4: Lymphoma 3. Fisher R
Page 226 and 227:
VACOP-B Plus Autologous Bone Marrow
Page 228 and 229:
194 Chapter 4: Lymphoma sequential
Page 230 and 231:
196 Chapter 4: Lymphoma Study desig
Page 232 and 233:
198 Chapter 4: Lymphoma 100 90 80 .
Page 234 and 235:
200 Chapter 4: Lymphoma Patients we
Page 236 and 237:
202 Chapter 4: Lymphoma 19. Fisher
Page 239 and 240:
Total Therapy With Tandem Transplan
Page 241 and 242:
Immune-Based Strategies to Improve
Page 243 and 244:
Schlossman et al. (sB2M), stage I d
Page 245 and 246:
Schlossman et al. 211 cells are rem
Page 247 and 248:
Schlossman et al. 213 Cohorts of pa
Page 249 and 250:
Schlossman et al. 215 Disease-free
Page 251 and 252:
Schlossman et al. 217 taken advanta
Page 253 and 254:
Schlossman et al. Hematol 34:49-60,
Page 255 and 256:
Schlossman et al. 221 41. Giralt S,
Page 257 and 258:
Harousseau and Attal 223 were rando
Page 259 and 260:
Harousseau and Altai 225 II—III M
Page 261 and 262:
Harousseau and Attal 227 Table 1. I
Page 263 and 264:
Harousseau and Attal Table 2. IFM 9
Page 265 and 266:
Syngeneic Transplantation in Multip
Page 267 and 268:
Gahrton et al. 233 patients were ma
Page 269 and 270:
Pretreatment With Alkylating Agents
Page 271 and 272:
Table 1. Patient characteristics Nu
Page 273 and 274:
Kiel et al. Figure 1. Quantitative
Page 275 and 276:
Kiel et al. 2 4 6 8 10 12 Number of
Page 277 and 278:
3:316-323,1997. Kiel et al. 243 6.
Page 279:
CHAPTER 6 BREAST CANCER
Page 282 and 283:
248 Chapter 6: Breast Cancer cells
Page 284 and 285:
250 Chapter 6: Breast Cancer breast
Page 286 and 287:
252 Chapter 6: Breast Cancer 10 n p
Page 288 and 289:
254 Chapter 6: Breast Cancer the ex
Page 290 and 291:
Detection of Cytokeratin + Cells in
Page 292 and 293:
258 Chapter 6: Breast Cancer cytoke
Page 294 and 295:
260 Chapter 6: Breast Cancer Table
Page 296 and 297:
Page 298 and 299:
264 Chapter 6: Breast Cancer minati
Page 300 and 301:
266 Chapter 6: Breast Cancer 18 mon
Page 302 and 303:
268 Chapter 6: Breast Cancer Tumor
Page 304 and 305:
270 Chapter 6: Breast Cancer Figure
Page 306 and 307:
272 Chapter 6: Breast Cancer cultur
Page 308 and 309:
Tandem PBSC-Supported High-Dose The
Page 310 and 311:
276 Chapter 6: Breast Cancer breast
Page 312 and 313:
278 Chapter 6: Breast Cancer effica
Page 314 and 315:
280 Chapter 6: Breast Cancer BSC Ha
Page 316 and 317:
282 Chapter 6: Breast Cancer proced
Page 318 and 319:
Page 320 and 321:
286 Chapter 6: Breast Cancer In 24
Page 322 and 323:
288 Chapter 6: Breast Cancer Cancer
Page 324 and 325:
High-Dose Chemotherapy With Autolog
Page 326 and 327:
Page 328 and 329:
294 Chapter 6: Breast Cancer receiv
Page 330 and 331:
296 Chapter 6: Breast Cancer of res
Page 332 and 333:
298 Chapter 6: Breast Cancer obtain
Page 334 and 335:
300 Chapter 6: Breast Cancer high-d
Page 336 and 337:
302 Chapter 6: Breast Cancer effect
Page 338 and 339:
304 Chapter 6: Breast Cancer three
Page 340 and 341:
306 Chapter 6: Breast Cancer patien
Page 342 and 343:
308 Chapter 6: Breast Cancer separa
Page 344 and 345:
Page 346 and 347:
312 Chapter 6: Breast Cancer 1.0-1
Page 348 and 349:
314 Chapter 6: Breast Cancer c JS S
Page 350 and 351:
316 Chapter 6: Breast Cancer 2 O X
Page 352 and 353:
318 Chapter 6: Breast Cancer progre
Page 354 and 355:
320 Chapter 6: Breast Cancer C 1.0-
Page 356 and 357:
Page 358 and 359:
Page 360 and 361:
326 Chapter 6: Breast Cancer An out
Page 362 and 363:
328 Chapter 6: Breast Cancer 4. Can
Page 364 and 365:
330 Chapter 6: Breast Cancer 33. Ov
Page 366 and 367:
An Aggressive Approach to Metastati
Page 368 and 369:
334 Chapter 6: Breast Cancer CD O 1
Page 370 and 371:
336 Chapter 6: Breast Cancer 1.0
Page 372 and 373:
Sequential High Dose Chemotherapy f
Page 374 and 375:
340 Chapter 6: Breast Cancer 10. He
Page 376 and 377:
342 Chapter 6: Breast Cancer conclu
Page 378 and 379:
344 Chapter 6: Breast Cancer after
Page 380 and 381:
Page 382 and 383:
348 Chapter 6: Breast Cancer re > '
Page 384 and 385:
350 Chapter 6: Breast Cancer BM K-1
Page 386 and 387:
352 Chapter 6: Breast Cancer regime
Page 388 and 389:
354 Chapter 6: Breast Cancer 1988 1
Page 390 and 391:
356 Chapter 6: Breast Cancer Doceta
Page 392 and 393:
Page 394 and 395:
360 Chapter 6: Breast Cancer DIFFER
Page 396 and 397:
Expression of C-ErbB-2/Her-2 in Pat
Page 398 and 399:
364 Chapter 6: Breast Cancer MATERI
Page 400 and 401:
366 Chapter 6: Breast Cancer weeks.
Page 402 and 403:
368 Chapter 6: Breast Cancer (P=0.0
Page 404 and 405:
370 Chapter 6: Breast Cancer result
Page 406 and 407:
372 Chapter 6: Breast Cancer ACKNOW
Page 408 and 409:
374 Chapter 6: Breast Cancer apy in
Page 411 and 412:
High-Dose Chemotherapy and Autologo
Page 413 and 414:
Stiff, Kerger, and Bayer 379 75 mg/
Page 415 and 416:
Table 1. Clinical characteristics S
Page 417 and 418:
Survival 1.00 .80 4 .60 i .40 1 .20
Page 419 and 420:
Stiff, Kerger, and Bayer 385 patien
Page 421 and 422:
57:278-285,1995. Stiff, Kerger, and
Page 423 and 424:
Abonour et al. 389 INTRODUCTION Wit
Page 425 and 426:
Abonour et al. 391 A more recent ex
Page 427 and 428:
Abonour et al. 393 DFS by Prognosti
Page 429 and 430:
Abonour et al. 395 6. Motzer RJ, Co
Page 431 and 432:
Leyvraz et al. 397 Table 1. Results
Page 433 and 434:
Table 3. ICE toxicity (172 cycles)
Page 435 and 436:
Leyvraz et al. 401 intensive treatm
Page 437 and 438:
Elias et al. (CAV) and with etoposi
Page 439 and 440:
Elias et al. tumor, or in the case
Page 441 and 442:
Elias et al. selection of patients
Page 443 and 444:
Elias et al. partial purge of the a
Page 445 and 446:
ProcASCO 16:456a, 1997. Elias et al
Page 447 and 448:
Elias et al. late dose intensificat
Page 449 and 450:
Elias et al. G, McCauley M, Gaynes
Page 451 and 452:
Transplantation With PBSC, Manipula
Page 453 and 454:
Takaue et al. 419 transfusion (day
Page 455 and 456:
Takaue et al. All tation, this proc
Page 457 and 458:
Rodenhuis et al. 423 INTRODUCTION H
Page 459 and 460:
mg/m 2 Rodenhuis et al. 425 in pati
Page 461 and 462:
Rodenhuis et al. All interest. One
Page 463 and 464:
Rodenhuis et al. 429 Figure 2. Prog
Page 465 and 466:
c 1000 -I Rodenhuis et al. 0 4 8 Ti
Page 467 and 468:
Rodenhuis et al. 433 First, a respo
Page 469 and 470:
Epirubicin Plus G-CSF-Elicited Peri
Page 471 and 472:
Carlo-Stella et al. 437 tissues fro
Page 473 and 474:
Carlo-Stella et al. 439 Epi 1 20 mg
Page 475 and 476:
A 140 -i 120- _i 100- CO 80 - O 60
Page 477 and 478:
Carlo-Stella et al. immediately evi
Page 479 and 480:
lastomas. Anticancer Drugs 8:174-18
Page 481:
CHAPTER 8 AUTOIMMUNE DISEASE
Page 484 and 485:
450 Chapter 8: Autoimmune Disease u
Page 486 and 487:
Autologous Blood Stem Cell Therapy
Page 488 and 489:
454 Chapter 8: Autoimmune Disease T
Page 490 and 491:
456 Chapter 8: Autoimmune Disease w
Page 492 and 493:
Page 494 and 495:
Page 496 and 497:
Page 498 and 499:
Hematopoietic Stem Ceil Transplanta
Page 500 and 501:
466 Chapter 8: Autoimmune Disease i
Page 502 and 503:
468 Chapter 8: Autoimmune Disease s
Page 504 and 505:
470 Chapter 8: Autoimmune Disease 1
Page 506 and 507:
Autologous Stem Cell Therapy in Aut
Page 508 and 509:
Page 510 and 511:
Autologous Hematopoietic Stem Cell
Page 512 and 513:
Page 514 and 515:
480 Chapter 8: Autoimmune Disease r
Page 517 and 518:
Presence in Pretransplant Marrow of
Page 519 and 520:
Table 1. Study 1 patient characteri
Page 521 and 522:
Radford et al. 487 1 2 3 4 5 6 7 8
Page 523 and 524:
Radford et al. 489 transplantation,
Page 525 and 526:
Importance of Marrow Doses and Mode
Page 527 and 528:
Gorin TC 199 medium and finally fro
Page 529 and 530:
Gorin 495 ABMT IN AL Engraftment on
Page 531 and 532:
Gorin Table 5. Engraftment accordin
Page 533 and 534:
Gorin 499 ABMT IN AL Outcome in rel
Page 535 and 536:
OS% Gorin 501 1 1 1 • • 0 i 1 1
Page 537 and 538:
Gorin 503 S, Carlier P, Giordano D,
Page 539 and 540:
15:769-775, 1995. Gorin 505 35. Dou
Page 541 and 542:
Long-Term Observations Following He
Page 543:
Deeg et al 509 Table 2. Secondary m
Page 547 and 548:
Gene Marking to Assess Tumor Contam
Page 549 and 550:
Heslop et al. 515 clonogenic assays
Page 551 and 552:
Heslop et al. 517 Disease Free Surv
Page 553 and 554:
Heslop et al. 519 providing the cli
Page 555 and 556:
Enrichment of Tumor Cells From Auto
Page 557 and 558:
Ross et al. post-TEC fraction was c
Page 559 and 560:
Ross et al. 525 Table 2. Results of
Page 561 and 562:
Ross et al. that the capture antibo
Page 563 and 564:
Combining Positive/Negative Selecti
Page 565 and 566:
Mapara et al. 531 products of patie
Page 567 and 568:
Mapara et al. 533 Hematopoietic col
Page 569 and 570:
Mapara et al. 535 A i m : P u r g i
Page 571 and 572:
Mapara et al. 537 A |_ «••«
Page 573 and 574:
Mapara et al. 539 11. Shpall EJ, Le
Page 575 and 576:
Tumor Purging Technologies: More Qu
Page 577 and 578:
Gee 543 argued that these two patie
Page 579 and 580:
Gee 545 immunomagnetic particles to
Page 581 and 582:
Gee 547 POSITIVE OR NEGATIVE? Given
Page 583 and 584:
Gee 549 autologous transplants of c
Page 585 and 586:
Behavior of Hematopoietic Stem Cell
Page 587 and 588:
Henschler et al. 553 MATERIALS AND
Page 589 and 590:
Table 1. Engraftment of human CD34
Page 591 and 592:
Henschler et al. 557 an increase of
Page 593 and 594:
Henschler et dl. 559 plantation for
Page 595 and 596:
CD34 Selection and Autografting in
Page 597 and 598:
Table 1. Patient characteristics, n
Page 599 and 600:
Voso et al. 565 The side scatter (S
Page 601 and 602:
Table 3. Immunophenotype of CD34 +
Page 603 and 604:
Voso et al. 569 neuroblastoma and a
Page 605 and 606:
Voso et al. 571 transplantation for
Page 607 and 608:
Neutrophils Days 100 Days to >500
Page 609 and 610:
Dicke et al. 575 CD34 Labeling Samp
Page 611 and 612:
Dicke et al. 577 Table 3. Platelet
Page 613 and 614:
Dicke et al. 579 3. Ager S, Scott M
Page 615 and 616:
Janssen et al. 581 PBSC products. H
Page 617 and 618:
Janssen et al. Table 1. Characteris
Page 619 and 620:
5X10 5 Janssen et ai. 585 In brief,
Page 621 and 622:
Janssen et al. CD34+ CELLS INFUSED/
Page 623 and 624:
1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2
Page 625 and 626:
Janssen et al. RELAPSE FREE SURVIVA
Page 627 and 628:
CD34 + Janssen et al. cells and CFU
Page 629 and 630:
Janssen et al. 595 8. Dercksen MW,
Page 631 and 632:
Janssen et al. 597 32. Sosman JA, S
Page 633:
CHAPTER 11 MINITRANSPLANTS
Page 636 and 637:
602 Chapter 11: Minitransplants to
Page 638 and 639:
604 Chapter 11: Minitransplants Tab
Page 640 and 641:
Page 642 and 643:
608 Chapter 11: Minitransplants tra
Page 644 and 645:
610 Chapter 11: Minitransplants 14.
Page 646 and 647:
Allogeneic Progenitor Cell Transpla
Page 648 and 649:
614 Chapter 11: Minitransplants 100
Page 650 and 651:
Page 652 and 653:
618 Chapter 11: Minitransplants all
Page 655 and 656:
Transduction of Primitive Hematopoi
Page 657 and 658:
Jordan et al. shown that such a hyb
Page 659 and 660:
Table 1. Initial findings with seve
Page 661 and 662:
Jordan et al. In preclinical studie
Page 663 and 664:
Molecular Intervention in Myeloma A
Page 665:
CHAPTER 13 IMMUNOTHERAPY
Page 668 and 669:
Immune-toxins Containing Pokeweed A
Page 670 and 671:
636 Chapter 13: Immunotherapy tumor
Page 672 and 673:
638 Chapter 13: Immunotherapy unide
Page 674 and 675:
640 Chapter 13: Immunotherapy lymph
Page 676 and 677:
642 Chapter 13: Immunotherapy accom
Page 678 and 679:
644 Chapter 13: Immunotherapy Figur
Page 680 and 681:
646 Chapter 13: Immunotherapy CD80P
Page 682 and 683:
648 Chapter 13: Immunotherapy are o
Page 684 and 685:
650 Chapter 13: Immunotherapy 23. F
Page 686 and 687:
652 Chapter 13: Immunotherapy 57. T
Page 688 and 689:
Adjuvant Immunotherapy in Conjuncti
Page 690 and 691:
656 Chapter 13: Immunotherapy mg/m
Page 692 and 693:
658 Chapter 13: Immunotherapy NHL a
Page 694 and 695:
660 Chapter 13: Immunotherapy tion
Page 696 and 697:
662 Chapter 13: Immunotherapy Table
Page 698 and 699:
664 Chapter 13: Immunotherapy leuke
Page 701 and 702:
The Brambell Receptor (FcRB) and th
Page 703 and 704:
5h P 11- V Junghans 669 o I 1 1 1 1
Page 705 and 706:
Junghans 10 20 30 40 IgG Concentrat
Page 707 and 708:
1001- 90 80 E 70 § 60 K g 50 u z 8
Page 709 and 710:
Junghans 675 Time, days Figure 8. B
Page 711 and 712:
Junghans 677 The site on Fc for int
Page 713 and 714:
Junghans 679 1969. 20. Junghans RP,
Page 715 and 716:
Approaches to the Radiation Dosimet
Page 717 and 718:
Fisher 683 bution to marrow dose is
Page 719 and 720:
Fisher 685 organ k per unit cumulat
Page 721 and 722:
Fisher 687 acetabulum. The curve is
Page 723 and 724:
Fisher 689 Table 2. Correlations be
Page 725 and 726:
Fisher 8. Sgouros G: Bone marrow do
Page 727:
Radioimmunotherapy for Malignant Ly
Page 731 and 732:
Induction of Graft-vs.-Malignancy a
Page 733 and 734:
Champlin, Khouri, and Giralt 699 is
Page 735 and 736:
Champlin, Khouri, and Girat 701 and
Page 737 and 738:
Champlin, Khouri, and Giralt 703 ti
Page 739 and 740:
Champlin, Khouri, and Giralt 705 A
Page 741 and 742:
Champlin, Khouri, and Giralt 707 E,
Page 743 and 744:
Whimbey 709 INTRODUCTION Infectious
Page 745 and 746:
Whimbey 711 CRVs are a common cause
Page 747 and 748:
Whimbey 713 antibody titers to RSV
Page 749 and 750:
Whimbey 715 toxic, less costly, and
Page 751 and 752:
Asymmetric Division as Measurable P
Page 753:
Neuropoiesis Peter Quesenberry, Car
Page 757 and 758:
Summary: Leukemia John Barrett Bone
Page 759 and 760:
Barrett New directions A role for i
Page 761 and 762:
Autologous Blood and Marrow Transpl
Page 763 and 764:
across page) Elfenbein 729 Examples
Page 765 and 766:
Elfenbein 731 Examples Contributors
Page 767 and 768:
Table 3. Types of clinical trials i
Page 769 and 770:
Strategies in Autologous Bone Marro
Page 771 and 772:
Summary: Lymphoma Armand Keating On
Page 773 and 774:
Rafat Abonour Indiana Univ. Cancer
Page 775 and 776:
H-Joachim Deeg Fred Hutchinson Canc
Page 777 and 778:
Richard P. Junghans Division of Hem
Page 779 and 780:
Peter J. Quesenberry Univ. of Massa
Page 781 and 782:
Linda T. Vahdat Columbia Presbyteri
Page 783 and 784:
DiStefano, Alfred 332 Dodero, Anna
Page 785 and 786:
Author Index 751 Ohno-Jones, S. 113
Page 787 and 788:
KEY WORD INDEX 4-HC 1 Brambell rece
Page 789:
Refractory anemia with excess blast
show all

autologous blood and marrow transplantation - Blog Science ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?